The MDM2/CDK4 amplicon: what your report means

What the report actually says

Amplification is not mutation. A mutation means the gene sequence itself has changed — a typo in the blueprint. Amplification means the blueprint is fine, but the cell has copied it over and over. Instead of two copies there are twenty, fifty or more.

MDM2 and CDK4 sit on the long arm of chromosome 12, in the 12q13-15 region. They lie close enough together that they are usually copied as a pair — which is why reports often say co-amplification. Other genes from the same neighbourhood can come along.

The consequence: far too much MDM2 protein. MDM2 normally keeps the tumour suppressor p53 in check — the guard that stops damaged cells. With a large excess of MDM2, p53 is held down permanently, even though the TP53 gene itself is usually entirely normal. CDK4 in turn drives the cell cycle forward. Together they produce a cell that is allowed to keep growing when it should not.

How it is tested

The reference test is FISH (fluorescence in situ hybridisation) on tumour tissue. Coloured probes bind to the MDM2 gene and to a control point on chromosome 12, and the signals are counted under the microscope. The ratio between the two counts says whether, and how strongly, the region is amplified. Reports usually give this as a quotient, for example “MDM2/CEP12 ratio”.

Immunohistochemistry for MDM2, CDK4 and p16 is faster and cheaper and is often run first. It is less clear-cut, though: it can mislead in both directions. On its own it is not enough to carry a diagnosis.³

Some centres add sequencing panels that capture copy number alongside other changes. That does not replace FISH, but it can complete the picture.

Which tumours carry the amplicon

This is the part that surprises many patients: the MDM2/CDK4 amplicon is not tied to one organ. The same molecular change sits behind diagnoses that look clinically unrelated — among them:

• Atypical lipomatous tumour / well-differentiated liposarcoma — slow growing, essentially never spreads, but can come back locally.
• Dedifferentiated liposarcoma (DDLPS) — usually arises out of the well-differentiated form, behaves more aggressively, often sits in the retroperitoneum.
• Intimal sarcoma — ultra-rare, grows in the inner wall of the pulmonary artery, the aorta or the heart, and is often mistaken for an embolism at first.³⁴
• Parosteal osteosarcoma — sits on the bone surface and carries a markedly better outlook than classic osteosarcoma.

Two things follow. First: the diagnosis on your report has become more precise, because the amplification underwrites it. Second: there are people with an entirely different diagnosis whose tumour carries the same change — and therefore a shared basis for research.

What it changes

The diagnosis becomes firmer

In fatty tumours, the finding separates a benign lipoma from an atypical lipomatous tumour. In vascular and cardiac tumours it supports the assignment to intimal sarcoma. That sounds technical, but it feeds straight into how surgery is planned and how follow-up is run.

Treatment belongs at a sarcoma centre

The single most important factor in these tumours is the first operation. It cannot simply be repeated. High-volume centres plan it differently — and the specialist societies recommend referral to a specialist centre before treatment starts, not after.

Trials can open up

A growing share of sarcoma research recruits by molecular change rather than by organ. A documented MDM2/CDK4 amplification can therefore make you eligible for trials whose title has nothing to do with your own diagnosis. The written FISH report is the entry ticket — keep it to hand.

Which classes of agent are under study here, and what the randomised data show, is set out in full on the further-reading pages below.

What you can ask your team

• Was the amplification confirmed by FISH, or only suspected on immunostaining?
• What is the ratio in the report, and how is it being interpreted?
• Has my case been presented at a sarcoma centre — and if not, what argues against it?
• Are there trials recruiting on this amplification that I might fit?
• Can I have a copy of the full pathology and molecular report?
• Is tumour tissue stored, in case further testing is needed later?

Common questions

Further reading

• MDM2 and CDK4 amplification, in full — with trial data and treatment options
• Dedifferentiated liposarcoma — course, treatment, numbers
• Trials that recruit by amplification
• What is intimal sarcoma?
• Your pathology report, line by line
• Second opinion & sarcoma centres